TY - JOUR

T1 - CRISPR/Cas9 as a Mutagenic Factor

AU - Шумега, Андрей Романович

AU - Павлов, Юрий Иванович

AU - Чиринскайте, Ангелина Валерьевна

AU - Рубель, Александр Анатольевич

AU - Инге-Вечтомов, Сергей Георгиевич

AU - Степченкова, Елена Игоревна

N1 - Shumega, A.R.; Pavlov, Y.I.; Chirinskaite, A.V.; Rubel, A.A.; Inge-Vechtomov, S.G.; Stepchenkova, E.I. CRISPR/Cas9 as a Mutagenic Factor. Int. J. Mol. Sci. 2024, 25, 823. https://doi.org/10.3390/ijms25020823

PY - 2024/1/9

Y1 - 2024/1/9

N2 - The discovery of the CRISPR/Cas9 microbial adaptive immune system has revolutionized the field of genetics, by greatly enhancing the capacity for genome editing. CRISPR/Cas9-based editing starts with DNA breaks (or other lesions) predominantly at target sites and, unfortunately, at off-target genome sites. DNA repair systems differing in accuracy participate in establishing desired genetic changes but also introduce unwanted mutations, that may lead to hereditary, oncological, and other diseases. New approaches to alleviate the risks associated with genome editing include attenuating the off-target activity of editing complex through the use of modified forms of Cas9 nuclease and single guide RNA (sgRNA), improving delivery methods for sgRNA/Cas9 complex, and directing DNA lesions caused by the sgRNA/Cas9 to non-mutagenic repair pathways. Here, we have described CRISPR/Cas9 as a new powerful mutagenic factor, discussed its mutagenic properties, and reviewed factors influencing the mutagenic activity of CRISPR/Cas9.

AB - The discovery of the CRISPR/Cas9 microbial adaptive immune system has revolutionized the field of genetics, by greatly enhancing the capacity for genome editing. CRISPR/Cas9-based editing starts with DNA breaks (or other lesions) predominantly at target sites and, unfortunately, at off-target genome sites. DNA repair systems differing in accuracy participate in establishing desired genetic changes but also introduce unwanted mutations, that may lead to hereditary, oncological, and other diseases. New approaches to alleviate the risks associated with genome editing include attenuating the off-target activity of editing complex through the use of modified forms of Cas9 nuclease and single guide RNA (sgRNA), improving delivery methods for sgRNA/Cas9 complex, and directing DNA lesions caused by the sgRNA/Cas9 to non-mutagenic repair pathways. Here, we have described CRISPR/Cas9 as a new powerful mutagenic factor, discussed its mutagenic properties, and reviewed factors influencing the mutagenic activity of CRISPR/Cas9.

KW - редактирование генома

KW - CRISPR/Cas9

KW - мутации

KW - активность off-target

KW - Mutagens

KW - CRISPR-Cas Systems/genetics

KW - RNA, Guide, CRISPR-Cas Systems

KW - Mutagenesis/genetics

KW - Mutation

KW - genome editing

KW - mutations

KW - CRISPR/Cas9

KW - off-target activity

UR - https://www.mendeley.com/catalogue/d34ae4d4-1ce2-391c-a13f-47f594a12e0d/

U2 - 10.3390/ijms25020823

DO - 10.3390/ijms25020823

M3 - Review article

C2 - 38255897

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1422-0067

IS - 2

M1 - 823

ER -